1010115-57-7

Basic information

• Product Name: 4-Chloro-2-ethynyl-pyridine
• Synonyms: 4-Chloro-2-ethynyl-pyridine
• CAS NO: 1010115-57-7
• Molecular Formula: C7H4ClN
• Molecular Weight: 138
• Mol File: 1010115-57-7.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-Chloro-2-ethynyl-pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Chloro-2-ethynyl-pyridine(1010115-57-7)
• EPA Substance Registry System: 4-Chloro-2-ethynyl-pyridine(1010115-57-7)

Safety Data

• Hazardous Substances Data: 1010115-57-7(Hazardous Substances Data)

Usage

General Description

4-Chloro-2-ethynyl-pyridine is a chemical compound with the molecular formula C7H4ClN. It is a highly reactive and versatile building block used in the synthesis of various pharmaceuticals, agrochemicals, and functional materials. The presence of a chloro and an ethynyl group in its structure makes it useful in the preparation of various biologically active molecules. It is also utilized in the production of dyes, polymers, and other specialty chemicals. Additionally, 4-Chloro-2-ethynyl-pyridine has been studied for its potential application in the development of new drugs and as a reagent in organic synthesis. Overall, this chemical is an important and valuable tool in the field of organic chemistry and materials science.

Upstream product

• 22918-01-0 2-bromo-4-chloropyridine 
• 1066-54-2 trimethylsilylacetylene 
• 1010115-56-6 4-chloro-2-((trimethylsilyl)ethynyl)pyridine 

Relevant articles and documents

Arginine analogues incorporating carboxylate bioisosteric functions are micromolar inhibitors of human recombinant DDAH-1

Dimethylarginine dimethylaminohydrolase (DDAH) is a key enzyme involved in the metabolism of asymmetric dimethylarginine (ADMA) and N-monomethyl arginine (NMMA), which are endogenous inhibitors of the nitric oxide synthase (NOS) family of enzymes. Two isoforms of DDAH have been identified in humans, DDAH-1 and DDAH-2. DDAH-1 inhibition represents a promising strategy to limit the overproduction of NO in pathological states without affecting the homeostatic role of this important messenger molecule. Here we describe the design and synthesis of 12 novel DDAH-1 inhibitors and report their derived kinetic parameters, IC50 and Ki. Arginine analogue 10a, characterized by an acylsulfonamide isosteric replacement of the carboxylate, showed a 13-fold greater inhibitory potential relative to the known DDAH-1 inhibitor, L-257. Compound 10a was utilized to study the putative binding interactions of human DDAH-1 inhibition using molecular dynamics simulations. The latter suggests that several stabilizing interactions occur in the DDAH-1 active-site, providing structural insights for the enhanced inhibitory potential demonstrated by in vitro inhibition studies.

BENZIMIDAZOLE CANNABINOID AGONISTS BEARING A SUBSTITUTED HETEROCYCLIC GROUP

The present invention is related to novel benzimidazole compounds of formula (I) having cannabinoid receptor agonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals, in particular humans.